JP2016516714A - 呼吸制御調節化合物およびそれを使用する方法 - Google Patents

呼吸制御調節化合物およびそれを使用する方法 Download PDF

Info

Publication number
JP2016516714A
JP2016516714A JP2016501967A JP2016501967A JP2016516714A JP 2016516714 A JP2016516714 A JP 2016516714A JP 2016501967 A JP2016501967 A JP 2016501967A JP 2016501967 A JP2016501967 A JP 2016501967A JP 2016516714 A JP2016516714 A JP 2016516714A
Authority
JP
Japan
Prior art keywords
pyrimido
pyrimidine
propyl
tetraamine
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516714A5 (enExample
Inventor
スコット ダクス
スコット ダクス
ジェイムズ ジョセフ メンセル
ジェイムズ ジョセフ メンセル
ビータ オゾラ
ビータ オゾラ
キリル シュービン
キリル シュービン
マリーナ マルジュガ
マリーナ マルジュガ
エドガーズ スナ
エドガーズ スナ
Original Assignee
ガリオン ファーマシューティカルズ インコーポレイテッド
ガリオン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガリオン ファーマシューティカルズ インコーポレイテッド, ガリオン ファーマシューティカルズ インコーポレイテッド filed Critical ガリオン ファーマシューティカルズ インコーポレイテッド
Publication of JP2016516714A publication Critical patent/JP2016516714A/ja
Publication of JP2016516714A5 publication Critical patent/JP2016516714A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Otolaryngology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2016501967A 2013-03-15 2014-03-13 呼吸制御調節化合物およびそれを使用する方法 Pending JP2016516714A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792185P 2013-03-15 2013-03-15
US61/792,185 2013-03-15
PCT/US2014/025792 WO2014151462A1 (en) 2013-03-15 2014-03-13 Novel breathing control modulating compounds, and methods of using same

Publications (2)

Publication Number Publication Date
JP2016516714A true JP2016516714A (ja) 2016-06-09
JP2016516714A5 JP2016516714A5 (enExample) 2017-04-20

Family

ID=51580966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501967A Pending JP2016516714A (ja) 2013-03-15 2014-03-13 呼吸制御調節化合物およびそれを使用する方法

Country Status (14)

Country Link
US (1) US9643971B2 (enExample)
EP (1) EP2968329A4 (enExample)
JP (1) JP2016516714A (enExample)
KR (1) KR20150143498A (enExample)
CN (1) CN105209041A (enExample)
AU (1) AU2014234095A1 (enExample)
BR (1) BR112015023671A2 (enExample)
CA (1) CA2905950A1 (enExample)
EA (1) EA201591693A1 (enExample)
HK (1) HK1219234A1 (enExample)
MX (1) MX2015013137A (enExample)
SG (1) SG11201507140PA (enExample)
WO (1) WO2014151462A1 (enExample)
ZA (1) ZA201507064B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105340281B (zh) 2013-07-05 2019-06-28 索尼公司 发送装置、发送方法、接收装置和接收方法
NO346258B1 (en) * 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
US20210244742A1 (en) * 2015-07-22 2021-08-12 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
WO2021021236A1 (en) * 2019-07-26 2021-02-04 Heteron Biotechnologies, Llc Breath analyzer and urea breath test method
KR20260053367A (ko) * 2023-08-14 2026-04-21 뉴림 파머슈티칼스(1991) 리미티드 Gal475 조성물 및 그의 사용 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
JPH09505807A (ja) * 1993-11-24 1997-06-10 敦翁 福永 プリン組成物および投与方法
US6232312B1 (en) * 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
JPS557430B2 (enExample) 1972-05-17 1980-02-25
US4963541A (en) 1989-02-22 1990-10-16 Abbott Laboratories Pyrimido-pyrimidine lipoxygenase inhibiting compounds
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
EP2646423A4 (en) 2010-11-29 2014-04-30 Galleon Pharmaceuticals Inc NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR THE TREATMENT OF RESPIRATORY DISORDERS OR DISEASES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
JPH09505807A (ja) * 1993-11-24 1997-06-10 敦翁 福永 プリン組成物および投与方法
US6232312B1 (en) * 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, JPN6017043535, 2000, pages 585 - 589, ISSN: 0003828912 *
J. MED. CHEM., vol. 47(20), JPN6017043538, 2004, pages 4905 - 4922, ISSN: 0003828913 *
J. MED. CHEM., vol. 50(16), JPN6017043532, 2007, pages 3906 - 3920, ISSN: 0003828911 *

Also Published As

Publication number Publication date
EA201591693A1 (ru) 2016-03-31
MX2015013137A (es) 2016-05-05
US9643971B2 (en) 2017-05-09
WO2014151462A4 (en) 2014-11-13
AU2014234095A1 (en) 2015-10-08
EP2968329A1 (en) 2016-01-20
SG11201507140PA (en) 2015-10-29
CA2905950A1 (en) 2014-09-25
ZA201507064B (en) 2017-01-25
EP2968329A4 (en) 2016-09-28
HK1219234A1 (zh) 2017-03-31
KR20150143498A (ko) 2015-12-23
CN105209041A (zh) 2015-12-30
WO2014151462A1 (en) 2014-09-25
BR112015023671A2 (pt) 2017-07-18
US20160046635A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
JP6731427B2 (ja) 新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
JP2015537032A (ja) 経口バイオアベイラビリティーを有する呼吸制御調節化合物およびそれを使用する方法
US20080103162A1 (en) Antipruritics
US20120270848A1 (en) Novel Compositions and Therapeutic Methods Using Same
WO2012166909A1 (en) Compositions and methods for treating breathing control disorders or diseases
KR102629269B1 (ko) Olig2 활성의 억제
US9643971B2 (en) Breathing control modulating compounds, and methods of using same
JPH02134368A (ja) 新規なピリジル‐およびピリミジル誘導体
CN101970427A (zh) 治疗疼痛症状及其它失调的方法
JP2003520236A (ja) 不安方法
DE60132484T2 (de) Chinazolinderivate und -arzneimittel
EP4479399A1 (en) Adenosine ligands for the treatment of neurological disorders
WO2017101777A1 (zh) 吡咯并嘧啶化合物的盐
WO2025038783A1 (en) Adenosine ligands for the treatment of neurological disorders or chronic heart failure
JP2019535680A (ja) キナーゼを阻害する組成物及び方法
KR102014335B1 (ko) 5-ht7 수용체의 조절제로 작용하는 아릴피라졸릴피페라진 또는 아릴피라졸릴다이아제페인의 유도체 및 이를 포함하는 중추신경계 질환 치료 또는 예방용 약학 조성물
TW200406207A (en) Novel use
CA3215383A1 (en) Pharmaceutical composition, and preparation method therefor and application thereof
BR112017028487B1 (pt) Composto de modulação do controle da respiração e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180705